These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 20825624)

  • 1. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
    Dakin H; Fidler C; Harper C
    Value Health; 2010 Dec; 13(8):934-45. PubMed ID: 20825624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
    Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
    Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection.
    Jones J; Colquitt J; Shepherd J; Harris P; Cooper K
    Health Technol Assess; 2010 May; 14 Suppl 1():23-9. PubMed ID: 20507800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.
    Woo G; Tomlinson G; Nishikawa Y; Kowgier M; Sherman M; Wong DK; Pham B; Ungar WJ; Einarson TR; Heathcote EJ; Krahn M
    Gastroenterology; 2010 Oct; 139(4):1218-29. PubMed ID: 20600036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients.
    Chung GE; Cho EJ; Lee JH; Yoo JJ; Lee M; Cho Y; Lee DH; Kim HY; Yu SJ; Kim YJ; Yoon JH; Zoulim F
    Clin Mol Hepatol; 2017 Mar; 23(1):66-73. PubMed ID: 28190329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Telbivudine Versus Other Nucleos(t)ide Analogs on HBeAg Seroconversion and Other Outcomes in Patients with Chronic Hepatitis B: A Network Meta-Analysis.
    Liang X; Fan R; Sun J; Shaikh J; Taneja A; Gupta S; Hamed K
    Adv Ther; 2016 Apr; 33(4):519-31. PubMed ID: 26921204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis.
    Zhao P; Liu W; Zhao J; Guan Q
    Virol J; 2011 Feb; 8():75. PubMed ID: 21342505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
    Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
    World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
    Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
    Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of tenofovir in a kidney transplant patient with chronic hepatitis B and nucleos(t)ide multidrug resistance: a case report.
    Shan C; Yin GQ; Wu P
    J Med Case Rep; 2014 Aug; 8():281. PubMed ID: 25146249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.
    Dakin H; Sherman M; Fung S; Fidler C; Bentley A
    Pharmacoeconomics; 2011 Dec; 29(12):1075-91. PubMed ID: 22077579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA.
    Gao L; Trinh HN; Li J; Nguyen MH
    Aliment Pharmacol Ther; 2014 Mar; 39(6):629-37. PubMed ID: 24467455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [HBV vaccine escape mutations in a chronic hepatitis B patient treated with nucleos(t)ide analogues].
    Sayan M; Buğdacı MS
    Mikrobiyol Bul; 2013 Jul; 47(3):544-9. PubMed ID: 23971933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
    Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E
    Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients.
    Jung SK; Kim KA; Ha SY; Lee HK; Kim YD; Lee BH; Paik WH; Kim JW; Bae WK; Kim NH; Lee JS; Jwa YJ
    Clin Mol Hepatol; 2015 Mar; 21(1):41-8. PubMed ID: 25834801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients.
    Dienstag JL; Wei LJ; Xu D; Kreter B
    Clin Drug Investig; 2007; 27(1):35-49. PubMed ID: 17177578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B.
    Dakin H; Bentley A; Dusheiko G
    Value Health; 2010 Dec; 13(8):922-33. PubMed ID: 20825619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
    Buster EH; Schalm SW; Janssen HL
    Best Pract Res Clin Gastroenterol; 2008; 22(6):1093-108. PubMed ID: 19187869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of switching from lamivudine+adefovir to tenofovir disoproxil fumarate in virologically suppressed patients.
    Fasano M; Maggi P; Leone A; Volpe A; Fiore JR; Angarano G; Santantonio TA
    Dig Liver Dis; 2017 May; 49(5):530-534. PubMed ID: 28179096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients.
    Hadziyannis SJ
    Expert Opin Investig Drugs; 2007 Jun; 16(6):777-86. PubMed ID: 17501691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.